logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer's Xarelto Approved In EU For Preventing Stroke In Patients With AF

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission for use in two new indications, making it the only new oral anticoagulant approved in three indications across all 27 EU member states.

Xarelto is approved for preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, or AF, with one or more risk factors and for treatment of deep vein thrombosis, or DVT, and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults. It is also approved for prevention of Venous Thromboembolism, or VTE, in adult patients undergoing elective hip or knee replacement surgery.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT